Business Wire
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
📈
AI Sentiment
Highly Positive
9/10
- Home
- NTRA
NTRA
Natera Inc.
as of 01-30-2026 2:27pm EST
$231.12
$0.36
-0.16%
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 32.9B | IPO Year: | 2015 |
| Target Price: | $249.53 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $256.36 | Next Earning Date: | 02-26-2026 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 33.77% | Revenue Growth (next year): | 16.92% |
AI-Powered NTRA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 77.36%
77.36%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Natera Inc. (NTRA)
Brophy Michael Burkes
Sell
CHIEF FINANCIAL OFFICER
NTRA Jan 29, 2026
Avg Cost/Share
$230.43
Shares
1,867
Total Value
$430,155.64
Owned After
59,059
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
1,200
Total Value
$285,194.88
Owned After
142,486
SEC Form 4
RABINOWITZ DANIEL
Sell
SEC. AND CHIEF LEGAL OFFICER
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
1,000
Total Value
$237,662.40
Owned After
225,147
SEC Form 4
Fesko John
Sell
PRESIDENT, CHIEF BUS. OFFICER
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
928
Total Value
$220,550.71
Owned After
175,540
SEC Form 4
Brophy Michael Burkes
Sell
CHIEF FINANCIAL OFFICER
NTRA Jan 28, 2026
Avg Cost/Share
$237.55
Shares
2,413
Total Value
$573,221.12
Owned After
59,059
Sheena Jonathan
Sell
Director, Other
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
191
Total Value
$45,393.52
Owned After
263,596
SEC Form 4
Chapman Steven Leonard
Sell
CEO AND PRESIDENT
NTRA Jan 28, 2026
Avg Cost/Share
$237.66
Shares
3,648
Total Value
$866,992.44
Owned After
213,180
SEC Form 4
Moshkevich Solomon
Sell
PRESIDENT, CLINICALDIAGNOSTICS
NTRA Jan 27, 2026
Avg Cost/Share
$240.53
Shares
1,013
Total Value
$243,658.21
Owned After
142,486
SEC Form 4
RABINOWITZ DANIEL
Sell
SEC. AND CHIEF LEGAL OFFICER
NTRA Jan 27, 2026
Avg Cost/Share
$240.53
Shares
886
Total Value
$213,110.73
Owned After
225,147
SEC Form 4
Fesko John
Sell
PRESIDENT, CHIEF BUS. OFFICER
NTRA Jan 27, 2026
Avg Cost/Share
$240.53
Shares
784
Total Value
$188,576.54
Owned After
175,540
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 29, 2026 | Sell | $230.43 | 1,867 | $430,155.64 | 59,059 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jan 28, 2026 | Sell | $237.66 | 1,200 | $285,194.88 | 142,486 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jan 28, 2026 | Sell | $237.66 | 1,000 | $237,662.40 | 225,147 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Jan 28, 2026 | Sell | $237.66 | 928 | $220,550.71 | 175,540 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jan 28, 2026 | Sell | $237.55 | 2,413 | $573,221.12 | 59,059 | |
| Sheena Jonathan | NTRA | Director, Other | Jan 28, 2026 | Sell | $237.66 | 191 | $45,393.52 | 263,596 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jan 28, 2026 | Sell | $237.66 | 3,648 | $866,992.44 | 213,180 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jan 27, 2026 | Sell | $240.53 | 1,013 | $243,658.21 | 142,486 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jan 27, 2026 | Sell | $240.53 | 886 | $213,110.73 | 225,147 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Jan 27, 2026 | Sell | $240.53 | 784 | $188,576.54 | 175,540 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
StockStory
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
➖
AI Sentiment
Neutral
5/10
Simply Wall St.
Is It Too Late To Consider Natera (NTRA) After A 4x Three Year Share Price Surge
📉
AI Sentiment
Negative
3/10
Insider Monkey
Lack of Natera (NTRA) Exposure Weighs on Voya MidCap Opportunities Fund Performance
➖
AI Sentiment
Neutral
5/10
Compare NTRA vs Leading Stocks
See how NTRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.